Last reviewed 2026-04-22 · How we verify

reducing Tacrolimus

Reducing tacrolimus dosage lowers the immunosuppressive burden in transplant recipients to minimize drug-related toxicity while maintaining graft tolerance.

Reducing tacrolimus dosage lowers the immunosuppressive burden in transplant recipients to minimize drug-related toxicity while maintaining graft tolerance. Used for Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver), Reduction of tacrolimus-related nephrotoxicity and neurotoxicity in stable transplant patients.

At a glance

Mechanism of action

Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 production. Dose reduction strategies aim to decrease nephrotoxicity, neurotoxicity, and metabolic complications while preserving adequate immunosuppression. This approach is particularly relevant in stable transplant patients where lower drug exposure may be sufficient to prevent rejection.

Approved indications

• Maintenance immunosuppression in solid organ transplant recipients (kidney, heart, liver)
• Reduction of tacrolimus-related nephrotoxicity and neurotoxicity in stable transplant patients

Common side effects

• Nephrotoxicity (dose-dependent)
• Neurotoxicity (tremor, headache, confusion)
• Hyperglycemia
• Hypertension
• Graft rejection (if under-immunosuppressed)

Key clinical trials

• Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
• Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
• MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
• ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (PHASE1, PHASE2)
• Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
• Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation (PHASE3)
• Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.